Acute myeloid leukemia

Indexed in Crossref

83 abstracts matching acute myeloid leukemia from the meeting's journal supplement, fetched live from Crossref 2026-11-12 08:33 UTC. This is a keyword search, not the complete abstract book.

• E18555
  Use of electronic patient reported outcomes (ePRO) to characterize patients with acute myeloid leukemia (AML) receiving intense and less intense treatment.

  Omer Hassan Jamy, Kayla Stewart, Nadia Still, Debra Wujcik
• 6527
  Response to HiDAC/mitoxantrone/venetoclax (HMV) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML).

  Apoorva Ravichandran, Miles Thomas, Rafael Madero Marroquin, Emily Dworkin et al.
• E18517
  Treatment outcomes and unmet needs in patients with acute myeloid leukemia (AML) who are ineligible for intensive induction chemotherapy (IC): A systematic literature review (SLR).

  Guillermo Garcia-Manero, Ruizhi Zhao, Thomas William LeBlanc
• E18619
  Assessment of racial and age disparities in response and survival among acute myeloid leukemia (AML) patients treated with hypomethylating agents (HMA) and venetoclax.

  Robin Haley Westervelt Mabry, Leslie R. Ellis, Matthew Joseph Wieduwilt, Bayard L. Powell et al.
• 6523
  Association of acute myeloid leukemia (AML) patient, disease, and molecular characteristics with a long-term (LT) response to olutasidenib.

  Justin M. Watts, Brian Andrew Jonas, Arnaud Pigneux, Andrew H. Wei et al.
• E18504
  Evaluating the cost per month of response for olutasidenib (OLU) versus ivosidenib (IVO) for patients with relapsed/refractory (R/R) mutant IDH1 (m IDH1 ) acute myeloid leukemia (AML).

  Yasmin Abaza, Rory Shallis, Amber Thomassen, Caitlin Smare et al.
• E13760
  Polypharmacy discussions in older adults with newly diagnosed acute myeloid leukemia (AML).

  Jie Yin, Marielle Jensen-Battaglia, Amesha Narpaul, Soroush Mortaz et al.
• 6512
  A randomized phase II study of selinexor added to standard induction and consolidation chemotherapy in adults with acute myeloid leukemia (AML).

  Timothy S. Pardee, Keri Renee Maher, Madelyn Burkart, Matthew Joseph Wieduwilt et al.
• 6511
  A prospective observational study to compare the efficacy, time toxicity, and cost of conventional 3+7 regimen versus azacitidine + venetoclax (AZA + VEN) as induction therapy in patients with acute myeloid leukemia (AML).

  Manju Sengar, Arvind Vaidyanathan, Hasmukh Jain, Bhausaheb Bagal et al.
• 6507
  Safety and efficacy of eganelisib in adults with higher-risk myelodysplastic syndrome (HR-MDS) or relapsed/refractory (R/R) acute myeloid leukemia (AML).

  Mendel Goldfinger, Anjali S. Advani, Irene Navarro Vicente, Jacqueline Suen Garcia et al.
• E13519
  Social determinants of health (SDOH) and barriers to allogeneic hematopoietic stem cell transplantation (HCT) in acute myeloid leukemia (AML) in a community setting.

  Soeb Usta, Susan H. Karass, Marie Liu, Nima Ghalehsari et al.
• 6531
  Myelodysplasia-related mutation dynamics and outcomes in newly diagnosed (ND) acute myeloid leukemia (AML) treated with low-intensity therapy (LIT).

  Naszrin Arani, Sanam Loghavi, Courtney Denton DiNardo, Gautam Borthakur et al.
• E18615
  Inpatient outcomes in acute myeloid leukemia: A contemporary national study.

  Lemchukwu Amaeshi, Jude O. Ossai, Michael Imeh
• 6503
  A multicenter phase Ib/II trial of azacitidine, venetoclax, and ivosidenib in IDH1 -mutated acute myeloid leukemia (AML).

  Jennifer Marvin-Peek, Jacqueline Suen Garcia, Gautam Borthakur, Nicholas James Short et al.
• E22641
  Development and evaluation of a dark kinase–based transcriptional score in acute myeloid leukemia.

  Shree Rath, Amar Lal
• TPS6600
  A phase 3 study of revumenib plus venetoclax/azacitidine in adults with newly diagnosed NPM1 -mutated or KMT2A -rearranged acute myeloid leukemia ineligible for intensive chemotherapy (EVOLVE-2/HO177/AMLSG35-24/ACT-HOV-AML-002).

  Geert Abraham Huls, Michael W. M. Kühn, Paresh Vyas, Hartmut Dohner et al.
• E18553
  Demographic patterns and survival outcomes in acute myeloid leukemia with t(6;9)(p23;q34); DEK–NUP214.

  Filip J. Sadurski, Alifya Lokhandwala, Rohit Sharma
• E23058
  Difference-in-differences analysis of age-specific survival gains in acute myeloid leukemia following venetoclax approval.

  Adnan Askari, Betsy Cliff, Kah Loh, Austin Wesevich
• 6533
  Can transcriptome-based risk modeling improve survival stratification across cytogenetic groups in acute myeloid leukemia?

  Amith Paruchuri, Arkansh Sharma, Lahari Kasa, Pavan Raju Kola
• 6518
  Early G-CSF after venetoclax-based induction for acute myeloid leukemia: Multicenter associations with infections, neutrophil recovery, and early mortality.

  Randa Elzein, Safa Elzein
• E18502
  Demographics and trends of acute myeloid leukemia among young adults in the United States and Puerto Rico, 1999-2021.

  Bishara Jahshan, Andy Veras Victoria, Syed Shahrukh Rizv
• E18520
  Outcomes of frailty among hospitalized patients with acute myeloid leukemia: A National Inpatient Sample analysis (2017–2022).

  Rafia Irfan Waheed, Hareem Tahir, Muhammad Zahid Anwar, Mahum Shahid
• E18525
  Forecasting the durability of overall survival benefit with gemtuzumab ozogamicin in acute myeloid leukemia: A cumulative and time-series meta-analysis.

  Fnu Sagar, Sakshi Bai, Madho Mal
• 10020
  Longitudinal genomic characterization of pediatric acute myeloid leukemia at diagnosis and relapse.

  Jagdish Prasad Meena, Harshita Makkar, Anita Chopra, Sameer Bakhshi et al.
• E18560
  Automated identification of phenotypically aberrant cells in acute myeloid leukemia MRD: An unsupervised machine learning approach.

  Ansh Kumar, Jake Silberg, Meindert Niemeijer, Robert Apilado et al.
• E18573
  Conditioning intensity and post-transplant outcomes in acute myeloid leukemia: A real-world analysis.

  Astha Koolwal Kapoor, Yanal Mufeed Alnimer, Nicole Lisek, Chandra Kakarala et al.
• 6522
  Investigation of the role of IFITM3 and the PI3K/Akt axis in the acute myeloid leukemia tumor microenvironment.

  Fang Zhou, Yi Zhang, Jiaheng Guan, Lin Gui et al.
• E18508
  TP53 variant allele frequency as a driver of survival in TP53 -mutated acute myeloid leukemia.

  Rafeh Safdar, Chandra Kakarala, Reema Anjum, Astha Koolwal Kapoor et al.
• E18532
  Real-world outcomes of triplet therapy with hypomethylating agent, venetoclax, and FLT3 inhibitor versus doublet therapy in FLT3-mutated acute myeloid leukemia.

  Layal Sharrouf, Amir Tahmasb Fathi, Noura Abbas, Maher Abdul-Hay
• 6524
  Comparing induction strategies in acute myeloid leukemia: 10-year real-world experience with 7+3 and HMA/venetoclax.

  Chandra Kakarala, Rafeh Safdar, Reema Anjum, Astha Koolwal Kapoor et al.
• 6569
  Multimodal immunotherapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.

  Parveen Shiraz, Carlos Jose Rodriguez Santiago, Sonia Mei Fonseca, Kathy Phuong Le et al.
• E18543
  Real-world outcomes of TP53-mutated acute myeloid leukemia at a single institution.

  Alexandra Rusz, Melanie Kirk, Gautam Anand Shrivastava, Changtai Tian et al.
• E18505
  FLT3 inhibitors in acute myeloid leukemia: A network meta-analysis of phase III trials.

  Sameer Bhimani, Taimoor Nasir, Aniqa Baloch, Swapnil Surpur et al.
• 6554
  Allele-specific targeting of CD33 as a novel approach to enhance CAR-T selectivity in relapsed acute myeloid leukemia post–allogeneic transplantation.

  Guido David Pelaez, Anthony Irovic, Matthew Christopher
• E18545
  Prevalence of myelodysplastic syndrome and acute myeloid leukemia among hospitalizations with sickle cell disease: A National Inpatient Sample analysis.

  Rajiv Midha, Yang-Li Ou, Davin Turku, Ana Maria Colon Ramos et al.
• E18506
  Characteristics and clinical outcomes of newly diagnosed acute myeloid leukemia with MAPK pathway mutations: A referral-center retrospective analysis.

  Kensuke Takaoka, Sarah L. Mott, Ratdanai Yodsuwan, Sakditad Saowapa et al.
• E18540
  Clinical outcomes of venetoclax with and without azole antifungals in acute myeloid leukemia: A large real-world cohort study.

  Rama Nada, Akhil Deepak Vatvani, Dania Abu Zahra, Faiq Aldarabah et al.
• 6520
  The association of IDH co-mutations with treatment outcomes and overall survival in TP53 -mutated acute myeloid leukemia.

  Lukas Ronner, Sarah J. Skuli, Andrew Matthews, Catherine Lai
• 6548
  Time to response with HMA/venetoclax as a predictor of survival in acute myeloid leukemia: Analysis of 1- vs 2-cycle responders.

  Rafeh Safdar, Chandra Kakarala, Reema Anjum, Astha Koolwal Kapoor et al.
• E18536
  Translating meta-analytic risk into absolute survival: Projection modeling of secondary-type mutations in ELN-favorable NPM1-mutated acute myeloid leukemia.

  Nimra Shafi, Madho Mal, Syed Hassan Ali, Tehreem Asghar et al.
• E18541
  Intensive chemotherapy versus venetoclax–hypomethylating agents therapy for acute myeloid leukemia: A large real-world propensity-matched study.

  Salih Akgun, Kofi Boakye Opoku, Ecem Kalemoglu, Ahmed Demirci et al.
• E18537
  Use of optical genome mapping (OGM) to identify atypical or cryptic KMT2A (11q23) rearrangements and genomic structural mechanisms in acute myeloid leukemia.

  Jiani Chai, Robert Cimera, Ibadat Qayyum, Angela Scalise et al.
• 6534
  Mutation landscape and pathway-level disparities in Black versus White patients with acute myeloid leukemia.

  Chidiebube Ugwu, Tarfa Verinumbe, Olanipekun Lanny Ntukidem, Jude O. Ossai et al.
• E23207
  Terminal admission phenotype in acute myeloid leukemia: A national analysis of inpatient care intensity (NIS 2016–2023).

  Ramaditya Srinivasmurthy, Riccesha Hattin, Rishi Kumar Nanda, Jason Ta et al.
• TPS6601
  Phase 1, open-label, multi-center trial of RPT1G in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic syndromes/neoplasms.

  Dennise De Jesus Diaz, Aaron David Goldberg, Steve Abella, Caroline Robb et al.
• E24104
  Patient and caregiver knowledge and understanding of acute myeloid leukemia and satisfaction with oncologist communication.

  Austin Wesevich, Yingzhu Chen, Soroush Mortaz, Marielle Jensen-Battaglia et al.
• E18533
  Real-world comparative effectiveness of decitabine/cedazuridine plus venetoclax versus azacitidine plus venetoclax in older or unfit patients with newly diagnosed acute myeloid leukemia.

  Kofi Boakye Opoku, Salih Akgun, Emmanuel Kusi-Appiah, Resham Q. Mirza et al.
• TPS6599
  A phase I study of HPB-092, a dual FLT3/IRAK4 inhibitor, in relapsed or refractory acute myeloid leukemia.

  Mingyuan Sun, Yong Guo, He Zhou, Bing Zhang et al.
• E18515
  Comparative efficacy of antifungal prophylaxis in acute myeloid leukemia: A systematic review and meta-analysis.

  Cameron Hunter, Abdulrahman Alhajahjeh, Niroop Rajashekar, Alyssa Grimshaw et al.
• 6536
  Impact of variant topography of NPM1 mutations in acute myeloid leukemia.

  Markie S. Zimmer, Vikram Dhillon, Jeff Justin Aguilar, Dakshin Sitaram Padmanabhan et al.
• TPS6602
  A phase 3 study of revumenib in combination with intensive chemotherapy in patients with newly diagnosed NPM1 -mutated acute myeloid leukemia (REVEAL-ND NPM1).

  Eytan Stein, Ghayas C. Issa, Eduardo M. Rego, Kentaro Fukushima et al.
• E18523
  FLT3 inhibitors across the allogeneic transplant continuum in FLT3 -mutated acute myeloid leukemia: A systematic review and meta-analysis.

  Gowrishankar Palaniswamy, Prithvi Raghavan, Reshman Naga Kumar Jonnadula, Sai Lahari Sangaraju et al.
• E18535
  Comparative effectiveness of antibody-drug conjugates and targeted therapies in acute myeloid leukemia: A network meta-analysis of 15,412 patients.

  Shankar Biswas, Gaurav Kansal, Yashasvi Srivastava, Suchita Mylavarapu et al.
• E18518
  Comparative outcomes of FLAG-based versus standard 3+7 induction therapy in adults with newly diagnosed acute myeloid leukemia: A systematic review and meta-analysis.

  Mohammed Abdulgayoom, Soha Aboukhalaf, Mahmoud Osman, Nada Soliman et al.
• E18551
  Real-world comparative outcomes of intensive induction with 7+3 plus midostaurin versus azacitidine, venetoclax, and gilteritinib in FLT3-mutated acute myeloid leukemia.

  Oladayo Oyebanji, Uchenna Maureen Amaechi, Jude O. Ossai, Olanipekun Lanny Ntukidem et al.
• 6542
  Cladribine (CLAD) + low-dose AraC (LDAC) + venetoclax (VEN) in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome: Real-world analysis from a large community-based oncology practice.

  Janvi Bhatia, Pablo M. Bedano, Sumeet Bhatia, Jill Leslie et al.
• 11070
  Burden and site-specific spectrum of second primary malignancies after adult acute myeloid leukemia: A population-based SEER standardized incidence ratio study with latency-stratified risk profiling (2000–2022).

  Abat Khan, Shahzaib Maqbool, Mohammad Ebad Ur Rehman, Abdur Rehman et al.
• 6538
  Distinction of FLT3-ITD transcriptomic signature from FLT3-TKD and the frequency of this signature in acute myeloid leukemia without FLT3 mutation.

  Maher Albitar, Adam Albitar, Gustavo Rivero, Sally Agersborg et al.
• TPS6603
  A phase 2 study of olutasidenib in combination with azacitidine followed by olutasidenib maintenance after venetoclax plus a hypomethylating agent regimen for IDH1 -mutated acute myeloid leukemia (University of California Hematologic Malignancies Consortium Study 2441).

  Brian Andrew Jonas, Mohammad Bukari, Timothy Ferng, Deepa Jeyakumar et al.
• 6564
  Differentiating donor age on AML patient outcomes in the post-transplant cyclophosphamide contemporary era.

  John Behman, Muhammad Bilal Abid
• 6543
  Age and the genomic landscape of AML in precision oncology: An analysis using ASH HematOmics Program.

  Pranav Singh, Carlos Galvez
• 6547
  Phase 1 study of venetoclax combined with a 10-day regimen of decitabine in subjects with high-risk acute myeloid leukemia.

  Rafael Madero Marroquin, Rebecca Abraham, Anand Ashwin Patel, Thao Trang Nguyen et al.
• E18552
  Fitness classification and induction intensity selection in AML practice: A contemporary real-world cohort study.

  Jerry Qi, Tara Ostad, Justin Nguyen, Kiwon Park et al.
• 6544
  From infancy to young adulthood: Exploring the divergent genomic mechanisms that drive AML.

  Frank J. Scarpa, Madhuri Paul, John Michael Furgason, Nathan Montgomery
• 6530
  Older age as a predictor of post-transplant survival in newly diagnosed acute myeloid leukemia treated with HMA-venetoclax.

  Momna Warraich, Sudhesh Kumar, Mahnoor Fatima, Kristen McCullough et al.
• 6579
  Real-world outcomes of 7+3 versus azacitidine/venetoclax in CML transformed to AML.

  Muhammad Mujtaba Bhinder, Haris Sohail, Jennifer Collins, Salah Ud Din Safi et al.
• E18572
  Post-transplant outcomes stratified by induction therapy in patients with AML undergoing allogeneic transplantation.

  Nicole Lisek, Yanal Mufeed Alnimer, Chandra Kakarala, Astha Kapoor et al.
• 6519
  Molecular landscape and outcomes of Black and White adults diagnosed with acute myeloid leukemia.

  Eno-obong Blessing Udoh, Xiaoying Chen, Sarah Philip, Yazeed Sawalha et al.
• 6521
  A targeted phosphoproteomic assay to enable the prediction of response to intensive chemotherapy in acute myeloid leukemia.

  Gabriel Ghiaur, Josie A. Christopher, Weronika E. Borek, Luis Veiga Nobre et al.
• E18529
  Comparative burden of tumor lysis syndrome: ALL vs AML using a national U.S. dataset.

  Jawad Ahmed, Farheen Malik, Osama Mohiuddin, Dua Azim et al.
• E18511
  Impact of venetoclax dosing on outcomes in AML: A single-center real-world study.

  Cheryl H. Chang, Allison O. Taylor, Nia Michaela Mitchell, Jesse D. Troy et al.
• E18514
  Real-world treatment patterns and outcomes with olutasidenib after venetoclax in IDH1 -mutated AML using EHR data.

  Yasmin Abaza, Pinkal M. Desai, Jorge E. Cortes, Timothy Werwath et al.
• E18621
  Utilization patterns of venetoclax-based regimens for AML in a community-based setting and representative populational analyses.

  Natasha Amjed, Tyler G. Bruno, Swapna Thota, Mark Mitchell et al.
• 6562
  Impact of NPM1 co-mutation on post-transplant outcomes in MRG-mutated AML.

  Yanal Mufeed Alnimer, Astha Kapoor, Nicole Lisek, Chandra Kakarala et al.
• E18637
  Impact of erythrocytosis on overall survival, thrombotic events, and risk of transformation to AML in patients with myelofibrosis.

  Ahmad Abdalla, Jatin Thukral, Salman Jajja, Amanda Lussier et al.
• E18527
  Treatment patterns and outcomes with olutasidenib after venetoclax in IDH1-mutated AML using real-world data from a chart review.

  Pinkal M. Desai, Catherine Lai, Ashwin Kishtagari, Namrata Sonia Chandhok et al.
• 6525
  HMA plus venetoclax for 7- vs 14- vs 21- vs 28-day cycles in newly-diagnosed acute myeloid leukemia: ELN- and Mayo Genetic Risk–stratified analysis in 540 patients.

  Sudhesh Kumar, Momna Warraich, Mahnoor Fatima, Kristen McCullough et al.
• E23219
  Hospital-acquired sepsis as a driver of failure-to-rescue in AML and MDS: A national inpatient sample analysis, 2016–2023.

  Abbas Hussain, Ramaditya Srinivasmurthy, Rishi Kumar Nanda, Jason Ta et al.
• 6540
  A two-axis machine learning framework for cell-of-origin inference in AML: A proof-of-concept study.

  Jonathan Dan Andreadakis, Alexander Shkembi, Maria Olivera, Sandhya Maddali et al.
• 6505
  Revumenib as maintenance for AML following allogeneic stem cell transplantation.

  Hannah Goulart, Olayinka Okeleji, Courtney Denton DiNardo, Naval Guastad Daver et al.
• 12092
  Pilot RCT of a patient-centered communication intervention to promote values-based treatment decision-making in older adults with AML.

  Rachel Rodenbach, Atena Rahman, Yingzhu Chen, Emily Oh et al.
• E18524
  Determinants of survival in 356 patients failing frontline HMA-Ven for newly-diagnosed AML.

  Mahnoor Fatima, Sudhesh Kumar, Momna Warraich, Kristen McCullough et al.
• 6504
  Quizartinib in combination with decitabine and venetoclax for newly diagnosed and relapsed/refractory FLT3 -mutated AML.

  Musa Yilmaz, Muharrem Muftuoglu, Courtney Denton DiNardo, Tapan M. Kadia et al.